Skip to main content

Table 6 Comorbidities, health characteristics and associations with moderate-to-severe foot pain (MSFP)

From: Foot pain and foot health in an educated population of adults: results from the Glasgow Caledonian University Alumni Foot Health Survey

 

Women (n = 399)

Men (n = 192)

Total (n = 593) c

Odds ratio (95% CI) MSFP vs. no MSFP

Heart disease

4 (1.0)

7 (3.6)

11 (1.9)

0.56 (0.15–2.14)

 Treatment

4 (1.0)

5 (2.6)

9 (1.5)

 

 Limiting

3 (0.8)

0 (0.0)

3 (0.5)

 

High BP

36 (9.0)

22 (11.5)

58 (9.8)

1.85 (1.07–3.18) **

 Treatment

32 (8.0)

17 (8.9)

49 (8.3)

 

 Limiting

2 (0.5)

2 (1.0)

4 (0.7)

 

Lung Disease

12 (3.0)

4 (2.1)

16 (2.7)

0.91 (0.33–2.5)

 Treatment

12 (3.0)

3 (1.6)

15 (2.5)

 

 Limiting

7 (1.8)

2 (1.0)

9 (1.5)

 

Diabetes

8 (2.0)

13 (6.8)

21 (3.5)

0.75 (0.29–1.88

 Treatment

6 (1.5)

9 (4.7)

15 (2.5)

 

 Limiting

0 (0.0)

1 (0.5)

1 (0.2)

 

Ulcer/stomach

10 (2.5)

7 (3.6)

17 (2.9)

2.21 (0.83–5.89) *

 Treatment

10 (2.5)

5 (2.6)

15 (2.5)

 

 Limiting

2 (0.5)

1 (0.5)

3 (0.5)

 

Kidney disease d

2 (0.5)

3 (1.6)

5 (0.8)

2.29 (0.38–13.78)

 Treatment

1 (0.3)

1 (0.5)

2 (0.3)

 

 Limiting

0 (0.0)

1 (0.5)

1 (0.2)

 

Liver disease

0 (0.0)

0 (0.0)

0 (0.0)

–

 Treatment

0 (0.0)

0 (0.0)

0 (0.0)

 

 Limiting

0 (0.0)

0 (0.0)

0 (0.0)

 

Anaemia/blood

17 (4.3)

2 (1.0)

19 (3.2)

1.71 (0.69–4.28)

 Treatment

14 (3.5)

2 (1.0)

16 (2.7)

 

 Limiting

2 (0.5)

0 (0.0)

0 (0.0)

 

Cancer d

3 (0.8)

2 (1.0)

5 (0.8)

2.29 (0.38–13.78)

 Treatment

3 (0.8)

1 (0.5)

4 (0.7)

 

 Limiting

1 (0.3)

0 (0.0)

0 (0.0)

 

Depression

50 (12.5)

17 (8.9)

67 (11.2)

1.54 (0.93–2.57) *

 Treatment

41 (10.3)

10 (5.2)

51 (8.6)

 

 Limiting

25 (6.3)

7 (3.6)

22 (3.7)

 

Osteoarthritis

30 (7.5)

3 (1.6)

33 (5.6)

1.88 (0.93–3.81) *

 Treatment

14 (3.5)

1 (0.5)

15 (2.5)

 

 Limiting

19 (4.8)

3 (1.6)

22 (3.7)

 

Back pain

114 (28.6)

42 (21.9)

156 (26.3)

2.04 (1.41–2.95) **

 Treatment

34 (8.5)

17 (8.9)

51 (8.6)

 

 Limiting

43 (10.8)

14 (7.3)

57 (9.6)

 

Rheumatoid arthritis d

5 (1.3)

4 (2.1)

9 (1.5)

12.49 (1.55–100.54) **

 Treatment

5 (1.3)

2 (1.0)

7 (1.2)

 

 Limiting

1 (0.3)

3 (1.6)

4 (0.7)

 

Hip pain

61 (15.3)

9 (4.70)

70 (11.8)

2.72 (1.63–4.55) **

 Treatment

17 (4.3)

3 (1.6)

20 (3.4)

 

 Limiting

28 (7.0)

3 (1.6)

31 (5.2)

 

Knee pain

101 (25.3)

36 (18.8)

137 (23.1)

1.56 (1.06–2.30) **

 Treatment

30 (7.5)

9 (4.7)

39 (6.6)

 

 Limiting

54 (13.5)

19 (9.9)

73 (12.3)

 

Other

76 (19.0)

39 (20.3)

115 (19.4)

1.50 (0.99–2.27) *

 Treatment

38 (9.5)

18 (9.4)

56 (9.4)

 

 Limiting

15 (3.8)

15 (7.8)

30 (5.1)

 

SCQ total, median (IQR)

1 (0–3)

1 (0–3)

1 (0–3)

–

  ≥ 1 Medical condition

226 (56.6)

101 (52.6)

327 (55.1)

1.94 (1.38–2.72) **

  ≥ 2 Medical conditions (multi-morbidity)

110 (27.6)

50 (26.0)

160 (26.9)

2.04 (1.42–2.95) **

 Overweight a

193 (52.7)

122 (63.5)

316 (56.0)

2.01 (1.41–2.88) **

 Low physical activity b

45 (11.3)

18 (9.4)

64 (12.5)

0.93 (0.54–1.58)

 Current smoker

19 (4.8)

13 (6.8)

32 (5.4)

0.90 (0.43–1.88)

  1. an = 47 values missing
  2. bn = 82 values missing
  3. cincludes 2 cases who preferred not to disclose gender
  4. dFisher’s exact test conducted where cell frequencies < 5
  5. *significant at p < 0.2
  6. **significant at p < 0.05